导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.33% | 3510/4773 |
| 近一周 | -2.64% | 2743/5462 |
| 近一月 | -1.62% | 986/5421 |
| 近一季 | -0.49% | 842/5209 |
| 近半年 | -3.98% | 2384/4920 |
| 近一年 | -9.91% | 3368/4366 |
| 近两年 | 41.74% | 1804/2954 |
| 近三年 | 39.83% | 727/2253 |
| 成立以来 | 59.43% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.10% 3762/4961 |
-8.61% 3904/5312 |
- - |
- - |
| 2025 | 28.18% 1504/4813 |
15.50% 172/3635 |
4.03% 882/4076 |
12.64% 3050/4524 |
-5.29% 3530/4813 |
| 2024 | 25.27% 265/3463 |
-1.67% 1259/2808 |
10.58% 34/3014 |
15.83% 1614/3129 |
-0.54% 1455/3463 |
| 2023 | -10.02% 1256/2656 |
0.44% 1730/2280 |
0.08% 343/2385 |
-7.89% 1638/2515 |
-2.83% 539/2655 |
| 2022 | -4.49% 96/2207 |
-7.04% 235/1919 |
6.26% 736/2016 |
-14.83% 1161/2113 |
13.54% 99/2208 |
| 2021 | -12.05% 1120/1822 |
4.82% 135/1255 |
0.37% 1103/1330 |
-11.54% 1270/1466 |
-5.50% 1515/1822 |
| 2020 | -4.06% 962/1250 |
-13.69% 177/280 |
5.53% 218/295 |
-6.48% 1121/1164 |
12.62% 448/1184 |
| 2019 | 13.53% 705/1092 |
- - |
- - |
- - |
- - |
| 2018 | -7.95% 65/834 |
- - |
- - |
- - |
- - |
| 2017 | 28.75% 72/714 |
- - |
- - |
- - |
- - |
| 2016 | 8.89% 3/605 |
- - |
- - |
- - |
- - |
| 2015 | -4.25% 274/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏沪港通恒生ETF VS. 长安沪深300非周期A(740101) |